152 related articles for article (PubMed ID: 29262860)
1. Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens.
Gonzalez-Serna A; Ferrando-Martinez S; Tarancon-Diez L; De Pablo-Bernal RS; Dominguez-Molina B; Jiménez JL; Muñoz-Fernández MÁ; Leal M; Ruiz-Mateos E
J Transl Med; 2017 Dec; 15(1):259. PubMed ID: 29262860
[TBL] [Abstract][Full Text] [Related]
2. Loss of CD127 & increased immunosenescence of T cell subsets in HIV infected individuals.
Mojumdar K; Vajpayee M; Chauhan NK; Singh A; Singh R; Kurapati S
Indian J Med Res; 2011 Dec; 134(6):972-81. PubMed ID: 22310831
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.
Romero-Sánchez MC; Alvarez-Ríos AI; Bernal-Morell E; Genebat M; Vera F; Benhnia MR; Bravo-Urbieta J; Galera-Peñaranda C; de Pablo-Bernal RS; Abad-Carrillo MA; Leal M; Ruiz-Mateos E;
Antiviral Res; 2014 Nov; 111():26-32. PubMed ID: 25173576
[TBL] [Abstract][Full Text] [Related]
4. Partial recovery of senescence and differentiation disturbances in CD8
Eberhard JM; Ahmad F; Hong HS; Bhatnagar N; Keudel P; Schulze Zur Wiesch J; Schmidt RE; Meyer-Olson D
Clin Exp Immunol; 2016 Nov; 186(2):227-238. PubMed ID: 27377704
[TBL] [Abstract][Full Text] [Related]
5. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C; Ghosn J; Assoumou L; Soulié C; Peytavin G; Calvez V; Génin MA; Molina JM; Bouchaud O; Katlama C; Costagliola D;
J Antimicrob Chemother; 2008 Oct; 62(4):797-808. PubMed ID: 18641035
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Leeansyah E; Cameron PU; Solomon A; Tennakoon S; Velayudham P; Gouillou M; Spelman T; Hearps A; Fairley C; Smit de V; Pierce AB; Armishaw J; Crowe SM; Cooper DA; Koelsch KK; Liu JP; Chuah J; Lewin SR
J Infect Dis; 2013 Apr; 207(7):1157-65. PubMed ID: 23303810
[TBL] [Abstract][Full Text] [Related]
7. The proportion of CD57+ cells among effector CD8+ T cells is lower in HIV controllers compared with antiretroviral therapy-treated patients.
Henriquez S; Lécuroux C; Bitu M; Avettand-Fenoel V; Churaqui F; Catalan P; Chéret A; Boufassa F; Saez-Cirion A; Monceaux V; Meyer L; Goujard C; Lambotte O; Bourgeois C;
AIDS; 2019 Nov; 33(14):2137-2147. PubMed ID: 31688039
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
[TBL] [Abstract][Full Text] [Related]
9. Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection.
Shive CL; Clagett B; McCausland MR; Mudd JC; Funderburg NT; Freeman ML; Younes SA; Ferrari BM; Rodriguez B; McComsey GA; Calabrese LH; Sieg SF; Lederman MM
J Acquir Immune Defic Syndr; 2016 Apr; 71(5):483-92. PubMed ID: 26627102
[TBL] [Abstract][Full Text] [Related]
10. T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.
Tincati C; Savoldi A; Cannizzo ES; Bellistrì GM; Termini R; Garau M; Mancusi D; d'Arminio Monforte A; Marchetti G
Antivir Ther; 2016; 21(2):133-42. PubMed ID: 26355423
[TBL] [Abstract][Full Text] [Related]
11. CD127 Expression in Naive and Memory T Cells in HIV Patients Who Have Undergone Long-Term HAART.
Xu W; Li J; Wu Y; Zhou J; Zhong J; Lv Q; Shao H; Rao H
Lab Med; 2017 Feb; 48(1):57-64. PubMed ID: 27760802
[TBL] [Abstract][Full Text] [Related]
12. First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.
Poizot-Martin I; Allavena C; Delpierre C; Duvivier C; Obry-Roguet V; Cano CE; Guillouet de Salvador F; Rey D; Dellamonica P; Cheret A; Cuzin L; Katlama C; Cabié A; Hoen B;
Medicine (Baltimore); 2016 Oct; 95(41):e5087. PubMed ID: 27741125
[TBL] [Abstract][Full Text] [Related]
13. Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc.
Bernal E; Verdú JM; Vera F; Martinez O; Bravo J; Galera C; Muñoz A; Garcia E; Serrano J; Perez A; Vera C; Marín I; Cano A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19726. PubMed ID: 25397472
[TBL] [Abstract][Full Text] [Related]
14. T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis.
Merlini E; Luzi K; Suardi E; Barassi A; Cerrone M; Martínez JS; Bai F; D'Eril GV; Monforte AD; Marchetti G
PLoS One; 2012; 7(9):e46073. PubMed ID: 23029393
[TBL] [Abstract][Full Text] [Related]
15. Effects of different antigenic stimuli on thymic function and interleukin-7/CD127 system in patients with chronic HIV infection.
Castro P; Torres B; López A; González R; Vilella A; Nicolas JM; Gallart T; Pumarola T; Sánchez M; Leal M; Vallejo A; Bayas JM; Gatell JM; Plana M; García F
J Acquir Immune Defic Syndr; 2014 Aug; 66(5):466-72. PubMed ID: 24820104
[TBL] [Abstract][Full Text] [Related]
16. [The subpopulation CD4(+); CD25(+); Foxp3(+);/CD127(low/-); regulatory T cells in peripheral blood of HIV-infected patients correlated with disease progression].
Chen YL; Chen XR; Qin LX; Yang YF; Tang YM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1188-91. PubMed ID: 23127412
[TBL] [Abstract][Full Text] [Related]
17. The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.
Young J; Scherrer AU; Calmy A; Tarr PE; Bernasconi E; Cavassini M; Hachfeld A; Vernazza P; Günthard HF; Bucher HC;
Antivir Ther; 2019; 24(5):343-353. PubMed ID: 30985290
[TBL] [Abstract][Full Text] [Related]
18. The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients.
Di Biagio A; Ricci E; Viscoli C; Mesini A; Menzaghi B; Carenzi L; Orofino G; Parruti G; Martinelli C; Madeddu G; De Socio GV; Franzetti M; Quirino T; Bonfanti P;
Curr HIV Res; 2013 Apr; 11(3):179-86. PubMed ID: 23432466
[TBL] [Abstract][Full Text] [Related]
19. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study.
Mussini C; Lorenzini P; Cozzi-Lepri A; Marchetti G; Rusconi S; Gori A; Nozza S; Lichtner M; Antinori A; Cossarizza A; d'Arminio Monforte A;
BMC Med; 2018 May; 16(1):79. PubMed ID: 29807541
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-7 signalling defects in naive CD4+ T cells of HIV patients with CD4+ T-cell deficiency on antiretroviral therapy are associated with T-cell activation and senescence.
Tanaskovic S; Fernandez S; Price P; French MA
AIDS; 2014 Mar; 28(6):821-30. PubMed ID: 24499954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
